High expression of Testes-Specific protease 50 is associated with poor prognosis in colorectal carcinoma

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Zheng, Lei ^a   Xie, Ganfeng ^a   Duan, Guangjie ^a   Yan, Xiaochu ^a   Li, Qianwei ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; MESSENGER RNA; PROTEIN P53; PROTEINASE; TESTES SPECIFIC PROTEINASE 50; TUMOR MARKER; UNCLASSIFIED DRUG; SERINE PROTEINASE; TESTIS SPECIFIC PROTEASE 50; TESTIS-SPECIFIC PROTEASE 50;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; GENE LOCATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; ONCOGENE; PREDICTIVE VALUE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; TESTES SPECIFIC PROTEINASE 50 GENE; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; ADENOMA; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC; REGRESSION ANALYSIS; TUMOR CELL LINE;

ADENOMA; AGED; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; REGRESSION ANALYSIS; ROC CURVE; SERINE ENDOPEPTIDASES; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79960158467     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022203     Document Type: Article

References (72)

1. Yuan L, Shan J, De Risi D, Broome J, Lovecchio J, et al. (1999) Isolation of a novel gene, TSP50, by a hypomethylated DNA fragment in human breast cancer. Cancer Res 59: 3215-3221.
2. Shan J, Yuan L, Xiao Q, Chiorazzi N, Budman D, et al. (2002) TSP50, a possible protease in human testes, is activated in breast cancer epithelial cells. Cancer Res 62: 290-294.
3. Xu HP, Yuan L, Shan J, Feng H, (2004) Localization and expression of TSP50 protein in human and rodent testes. Urology 64: 826-832.
4. Xu H, Shan J, Jurukovski V, Yuan L, Li J, et al. (2007) TSP50 encodes a testis-specific protease and is negatively regulated by p53. Cancer Res 67: 1239-1245.
5. Wang M, Bao YL, Wu Y, Yu CL, Meng XY, et al. (2010) Basic FGF downregulates TSP50 expression via the ERK/Sp1 pathway. J Cell Biochem 111: 75-81.
6. Wang M, Bao YL, Wu Y, Yu CL, Meng X, et al. (2008) Identification and characterization of the human testes-specific protease 50 gene promoter. DNA Cell Biol 27: 307-314.
7. Zhou L, Bao YL, Zhang Y, Wu Y, Yu CL, et al. (2010) Knockdown of TSP50 inhibits cell proliferation and induces apoptosis in P19 cells. IUBMB Life 62: 825-832.
8. Song Z, Bao Y, Zhang Y, Mi X, Wu P, et al. (2011) Testes-specific protease 50 (TSP50) promotes cell proliferation through the activation of the NF-kappa beta (NF-kappaB) signaling pathway. Biochem J.
9. Kalejs M, Erenpreisa J, (2005) Cancer/testis antigens and gametogenesis: a review and "brain-storming" session. Cancer Cell Int 5: 4.
10. Van den Eynde BJ, van der Bruggen P, (1997) T cell defined tumor antigens. Curr Opin Immunol 9: 684-693.
11. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, et al. (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 94: 1914-1918.
12. Tureci O, Sahin U, Zwick C, Koslowski M, Seitz G, et al. (1998) Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc Natl Acad Sci U S A 95: 5211-5216.
13. Scanlan MJ, Altorki NK, Gure AO, Williamson B, Jungbluth A, et al. (2000) Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. Cancer Lett 150: 155-164.
14. Tureci O, Sahin U, Koslowski M, Buss B, Bell C, et al. (2002) A novel tumour associated leucine zipper protein targeting to sites of gene transcription and splicing. Oncogene 21: 3879-3888.
15. Loriot A, Boon T, De Smet C, (2003) Five new human cancer-germline genes identified among 12 genes expressed in spermatogonia. Int J Cancer 105: 371-376.
16. Peng JR, Chen HS, Mou DC, Cao J, Cong X, et al. (2005) Expression of cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parameters. Cancer Lett 219: 223-232.
17. Houet L, Veelken H, (2006) Active immunotherapy of multiple myeloma. Eur J Cancer 42: 1653-1660.
18. Huang Y, Wang Y, Wang M, Sun B, Li Y, et al. (2008) Differential methylation of TSP50 and mTSP50 genes in different types of human tissues and mouse spermatic cells. Biochem Biophys Res Commun 374: 658-661.
19. Feinberg AP, Vogelstein B, (1983) Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301: 89-92.
20. Cui H, Cruz-Correa M, Giardiello FM, Hutcheon DF, Kafonek DR, et al. (2003) Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 299: 1753-1755.
21. Kato K, Maesawa C, Itabashi T, Fujisawa K, Otsuka K, et al. (2009) DNA hypomethylation at the CpG island is involved in aberrant expression of the L1 cell adhesion molecule gene in colorectal cancer. Int J Oncol 35: 467-476.
22. Martelange V, De Smet C, De Plaen E, Lurquin C, Boon T, (2000) Identification on a human sarcoma of two new genes with tumor-specific expression. Cancer Res 60: 3848-3855.
23. Yokoe T, Tanaka F, Mimori K, Inoue H, Ohmachi T, et al. (2008) Efficient identification of a novel cancer/testis antigen for immunotherapy using three-step microarray analysis. Cancer Res 68: 1074-1082.
24. Chen Z, Li M, Yuan Y, Wang Q, Yan L, et al. (2010) Cancer/testis antigens and clinical risk factors for liver metastasis of colorectal cancer: a predictive panel. Dis Colon Rectum 53: 31-38.
25. Caballero OL, Chen YT, (2009) Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 100: 2014-2021.
26. Lan YT, Chang SC, Li AF, Lin TC, Chen WS, et al. (2007) p53 protein accumulation as a prognostic marker in sporadic colorectal cancer. Int J Colorectal Dis 22: 499-506.
27. Gallego MG, Acenero MJ, Ortega S, Delgado AA, Cantero JL, (2000) Prognostic influence of p53 nuclear overexpression in colorectal carcinoma. Dis Colon Rectum 43: 971-975.
28. Noske A, Lipka S, Budczies J, Muller K, Loddenkemper C, et al. (2009) Combination of p53 expression and p21 loss has an independent prognostic impact on sporadic colorectal cancer. Oncol Rep 22: 3-9.
29. Galizia G, Ferraraccio F, Lieto E, Orditura M, Castellano P, et al. (2004) Prognostic value of p27, p53, and vascular endothelial growth factor in Dukes A and B colon cancer patients undergoing potentially curative surgery. Dis Colon Rectum 47: 1904-1914.
30. Kwak JM, Lee HJ, Kim SH, Kim HK, Mok YJ, et al. (2010) Expression of protein S100A4 is a predictor of recurrence in colorectal cancer. World J Gastroenterol 16: 3897-3904.
31. Pereira H, Silva S, Juliao R, Garcia P, Perpetua F, (1997) Prognostic markers for colorectal cancer: expression of P53 and BCL2. World J Surg 21: 210-213.
32. Starzynska T, Bromley M, Marlicz K, Roberts SA, Ucinski M, et al. (1997) Accumulation of p53 in relation to long-term prognosis in colorectal carcinoma. Eur J Gastroenterol Hepatol 9: 183-186.
33. Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, et al. (2005) The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 23: 7518-7528.
34. Pancione M, Forte N, Fucci A, Sabatino L, Febbraro A, et al. (2010) Prognostic role of beta-catenin and p53 expression in the metastatic progression of sporadic colorectal cancer. Hum Pathol 41: 867-876.
35. Hilska M, Collan YU, VJ OL, Kossi J, Hirsimaki P, et al. (2005) The significance of tumor markers for proliferation and apoptosis in predicting survival in colorectal cancer. Dis Colon Rectum 48: 2197-2208.
36. Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, et al. (2001) Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344: 1196-1206.
37. Elsaleh H, Powell B, Soontrapornchai P, Joseph D, Goria F, et al. (2000) p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes' C colon carcinoma. Oncology 58: 52-59.
38. Chen MF, Lee KD, Yeh CH, Chen WC, Huang WS, et al. (2010) Role of peroxiredoxin I in rectal cancer and related to p53 status. Int J Radiat Oncol Biol Phys 78: 868-878.
39. Ogino S, Kirkner GJ, Nosho K, Irahara N, Kure S, et al. (2008) Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res 14: 8221-8227.
40. Lyall MS, Dundas SR, Curran S, Murray GI, (2006) Profiling markers of prognosis in colorectal cancer. Clin Cancer Res 12: 1184-1191.
41. Resnick MB, Routhier J, Konkin T, Sabo E, Pricolo VE, (2004) Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res 10: 3069-3075.
42. Bouzourene H, Gervaz P, Cerottini JP, Benhattar J, Chaubert P, et al. (2000) p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur J Cancer 36: 1008-1015.
43. Smyth EF, Sharma A, Sivarajasingham N, Hartley J, Monson JR, et al. (2004) Prognostic implications of hMLH1 and p53 immunohistochemical status in right-sided colon cancer. Dis Colon Rectum 47: 2086-2091; discussion 2091-2082.
44. Bourdon JC, (2007) p53 and its isoforms in cancer. British Journal of Cancer 97: 277-282.
45. Marcel V, Perrier S, Aoubala M, Ageorges S, Groves MJ, et al. (2010) Delta 160p53 is a novel N-terminal p53 isoform encoded by Delta 133p53 transcript. Febs Letters 584: 4463-4468.
46. Machado-Silva A, Perrier S, Bourdon JC, (2010) p53 family members in cancer diagnosis and treatment. Seminars in Cancer Biology 20: 57-62.
47. Samowitz WS, Curtin K, Ma KN, Edwards S, Schaffer D, et al. (2002) Prognostic significance of p53 mutations in colon cancer at the population level. Int J Cancer 99: 597-602.
48. Westra JL, Schaapveld M, Hollema H, de Boer JP, Kraak MM, et al. (2005) Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol 23: 5635-5643.
49. Chang SC, Lin JK, Yang SH, Wang HS, Li AF, et al. (2006) Relationship between genetic alterations and prognosis in sporadic colorectal cancer. Int J Cancer 118: 1721-1727.
50. Mollevi DG, Serrano T, Ginesta MM, Valls J, Torras J, et al. (2007) Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection. Carcinogenesis 28: 1241-1246.
51. Vidaurreta M, Maestro ML, Sanz-Casla MT, Rafael S, Veganzones S, et al. (2008) Colorectal carcinoma prognosis can be predicted by alterations in gene p53 exons 5 and 8. Int J Colorectal Dis 23: 581-586.
52. Katkoori VR, Jia X, Shanmugam C, Wan W, Meleth S, et al. (2009) Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin Cancer Res 15: 2406-2416.
53. El-Serafi MM, Bahnassy AA, Ali NM, Eid SM, Kamel MM, et al. (2010) The prognostic value of c-Kit, K-ras codon 12, and p53 codon 72 mutations in Egyptian patients with stage II colorectal cancer. Cancer 116: 4954-4964.
54. Conlin A, Smith G, Carey FA, Wolf CR, Steele RJ, (2005) The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut 54: 1283-1286.
55. de Jong KP, Gouw AS, Peeters PM, Bulthuis M, Menkema L, et al. (2005) P53 mutation analysis of colorectal liver metastases: relation to actual survival, angiogenic status, and p53 overexpression. Clin Cancer Res 11: 4067-4073.
56. Lagerstedt KK, Kressner U, Lonnroth C, Nordgren S, Lundholm K, (2005) The role of combined allelic imbalance and mutations of p53 in tumor progression and survival following surgery for colorectal carcinoma. Int J Oncol 27: 1707-1715.
57. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, et al. (2007) Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 43: 1348-1360.
58. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, et al. (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24: 5313-5327.
59. Kim J, Reber HA, Hines OJ, Kazanjian KK, Tran A, et al. (2006) The clinical significance of MAGEA3 expression in pancreatic cancer. Int J Cancer 118: 2269-2275.
60. Riener MO, Wild PJ, Soll C, Knuth A, Jin B, et al. (2009) Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular carcinoma. Int J Cancer 124: 352-357.
61. Velazquez EF, Jungbluth AA, Yancovitz M, Gnjatic S, Adams S, et al. (2007) Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)-correlation with prognostic factors. Cancer Immun 7: 11.
62. Sun LC, Chu KS, Cheng SC, Lu CY, Kuo CH, et al. (2009) Preoperative serum carcinoembryonic antigen, albumin and age are supplementary to UICC staging systems in predicting survival for colorectal cancer patients undergoing surgical treatment. BMC Cancer 9: 288.
63. Gaber A, Nodin B, Hotakainen K, Nilsson E, Stenman UH, et al. (2010) Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients. BMC Cancer 10: 498.
64. Li M, Li JY, Zhao AL, He JS, Zhou LX, et al. (2009) Comparison of carcinoembryonic antigen prognostic value in serum and tumour tissue of patients with colorectal cancer. Colorectal Dis 11: 276-281.
65. Bhatnagar J, Tewari HB, Bhatnagar M, Austin GE, (1999) Comparison of carcinoembryonic antigen in tissue and serum with grade and stage of colon cancer. Anticancer Res 19: 2181-2187.
66. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, et al. (2010) Colorectal cancer. Lancet 375: 1030-1047.
67. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, et al. (2000) Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124: 979-994.
68. Duan GJ, Yan XC, Bian XW, Li J, Chen X, (2004) [The significance of beta-catenin and matrix metalloproteinase-7 expression in colorectal adenoma and carcinoma]. Zhonghua Bing Li Xue Za Zhi 33: 518-522.
69. Takikita M, Altekruse S, Lynch CF, Goodman MT, Hernandez BY, et al. (2009) Associations between selected biomarkers and prognosis in a population-based pancreatic cancer tissue microarray. Cancer Res 69: 2950-2955.
70. Matta A, Tripathi SC, DeSouza LV, Grigull J, Kaur J, et al. (2009) Heterogeneous ribonucleoprotein K is a marker of oral leukoplakia and correlates with poor prognosis of squamous cell carcinoma. Int J Cancer 125: 1398-1406.
71. Matta A, DeSouza LV, Shukla NK, Gupta SD, Ralhan R, et al. (2008) Prognostic significance of head-and-neck cancer biomarkers previously discovered and identified using iTRAQ-labeling and multidimensional liquid chromatography-tandem mass spectrometry. J Proteome Res 7: 2078-2087.
72. Tamada S, Shibahara H, Higashi M, Goto M, Batra SK, et al. (2006) MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Clin Cancer Res 12: 4257-4264.